Article Text
Statistics from Altmetric.com
Aspirin and cognition
Long-term use of low dose aspirin does not protect against cognitive decline in healthy and mostly white women aged 65 or more. This is the finding of a randomised, double-blind, placebo-controlled trial in which low dose aspirin was given to a subset of 6377 women participating in the Women’s health study. At the initial assessment (mean 5.6 years after randomisation) cognitive performance in the aspirin group was similar to that of the placebo group (mean difference in global score −0.01, 95% CI −0.04 to 0.02). According to the authors this trial does not support previous laboratory and epidemiological evidence that suggested that aspirin and other anti-inflammatory drugs may be protective against dementia.
Herpes simplex encephalitis
Herpes simplex encephalitis continues to be associated with poor long-term outcomes despite treatment with intravenous aciclovir. This is the finding of a simple prospective register-based observational study of children done in Toronto, Canada. Of 322 children with acute …
Other content recommended for you
- Diagnosis and treatment of viral encephalitis
- Herpes simplex virus (HSV) encephalitis in a young man: an unusual course
- Encephalitis in children
- Encephalitis: help from guidelines
- Herpes simplex virus encephalitis involving the right thalamus
- Thymoma associated paraneoplastic encephalitis (TAPE), a potential cause of limbic encephalitis
- High-grade glioma mimicking acute viral encephalitis − three case reports
- VIRAL ENCEPHALITIS: CAUSES, DIFFERENTIAL DIAGNOSIS, AND MANAGEMENT
- Severe chorea with positive anti-basal ganglia antibodies after herpesencephalitis
- Herpes simplex virus encephalitis in a patient receiving ustekinumab associated with extensive cerebral oedema and brainshift successfully treated by immunosuppression with dexamethasone